Canada Launches Portal To Proactively Disclose Clinical Data On Approved Drugs, Devices
Executive Summary
Following in the footsteps of the European Medicines Agency, Canada has launched a publicly-accessible portal to proactively disclose clinical trial information on approved drugs and medical devices that was hitherto considered confidential.
You may also be interested in...
It’s Started: EMA Proactively Publishes Clinical Data On New Drugs
The European Medicines Agency has delivered on its promise to grant public access to clinical reports that form the basis of its recommendations to the European Commission on whether or not a medicine should be authorized for use in the EU.
Wait over for landmark EMA policy on trial data access
Nearly all of the clinical trial data in new drug marketing applications that are submitted to the European Medicines Agency for evaluation after 1 January 2015 will be made available to the public following the drug's approval, the agency's eagerly-awaited final policy on proactive publication of trial data has revealed1-3.
EMA Says Yes To BMS’ Sotyktu But Turns Down Ipsen’s Sohonos
The European Medicines Agency has recommended pan-EU marketing approval for four medicines but turned down Ipsen’s treatment for an ultra-rare bone disorder. It has also OK’d new uses of seven already-approved drugs and is reviewing efficacy concerns regarding Novartis’ sickle cell medicine.